Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Adding trastuzumab (Herceptin) to standard chemotherapy for HER2-positive early breast cancer significantly reduces recurrence risk and improves overall survival, but it also increases…
NEW YORK (Reuters Health) – Adding cladribine to the standard induction regimen for adults with acute myeloid leukemia (AML) increases the complete remission rate and consequent survival, a…
NEW YORK (Reuters Health) – Adding bevacizumab (Avastin, Genentech) to standard carboplatin and paclitaxel chemotherapy offers little clinical benefit in patients aged 65 and older with non-small cell…
NEW YORK (Reuters Health) – Older patients with small localized kidney tumors treated with partial nephrectomy live longer than those treated with radical nephrectomy, a new study suggests.…
NEW YORK (Reuters Health) – A meta-analysis of individual patient data found no differences in overall survival, progression-free survival, and objective response rate between cisplatin- and carboplatin-based chemotherapy…
NEW YORK (Reuters Health) – Adjuvant tamoxifen after surgery and radiation reduces subsequent ipsilateral and contralateral breast cancers in women with estrogen-receptor (ER)-positive ductal carcinoma in situ (DCIS),…
NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal…
NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal…
NEW YORK (Reuters Health) – In general, adding pemetrexed to cisplatin therapy does not improve overall survival (OS) in patients with recurrent or metastatic head and neck cancer,…
NEW YORK (Reuters Health) – Disease-free survival is not improved after resection of stage III colon cancer when cetuximab is added to chemotherapy with leucovorin, fluorouracil, and oxaliplatin…
